The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Development strategies designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes ...